
Novartis will acquire the dermatology generics firm Fougera for $1.53 billion in cash. Novartis’ generic unit Sandoz is conducting the …

A new survey of leading international companies has found Roche and Novartis have the best websites in the pharma sector. …
Novartis chief executive Joe Jimenez has said that production at the firm’s troubled consumer health plant in Lincoln, Nebraska, will …
Generic competition and problems at a US plant were among the reasons why Novartis’ sales and profit dipped in the …
The GMC has decided not to relax guidelines on off-label prescribing when a licensed alternative exists. The GMC’s current rules …

Novartis has unveiled plans to build a new manufacturing facility at its site in Stein, Switzerland, just weeks after calling …

A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …

A safety review of Novartis’ MS treatment Gilenya has concluded the drug should stay on the market, but that patients …

Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
Novartis has selected Turkey as its headquarters for central Asia, the Middle East and Africa and intends to set up …

Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million. The deal has been …

A long-running battle over the patent of cancer treatment Glivec in India is about to reach its dramatic climax.India’s Supreme …
Novartis has appointed Brian McNamara to the position of division head of its OTC (Over-the-Counter) business with immediate effect. McNamara …

GlaxoSmithKline is the latest company to be affected by manufacturing glitches at Novartis’ troubled facility in Lincoln, Nebraska, having been …

Glivec has gained EU approval for extended use after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).The drug …